Best- and Worst-Case AIDS Epidemic Scenarios Discussed at Davos
By Emily Bass
This January’s World Economic Forum (WEF) meeting in Davos, Switzerland featured a three-hour workshop on “The Economic Impact of HIV/AIDS.”
Vol. 07, No. 1, Feb.-Apr. 2003
VaxGen, Merck's Program, Boost from Cytokines?, VaxGen Trial, Does Gender Matter?, Hormonal Contraceptive, EU Launches African Clinical Trials, Rights-Based Approach to AIDS Research, Best- and Worst-Case AIDS Epidemic, IAVI News, Vaccine Briefs
Can DNA Vaccines Get a Boost from Cytokines?
By Mark Boaz and Richard Jefferys*
Although DNA-based vaccines are beingdeveloped against many diseases, results in humans have not lived up to the initial promise shown in animal models.
Does Gender Matter for HIV Vaccines?
New Approaches to an Open Question
European Union Launches African Clinical Trials Program
By Mark Boaz
On 27 March 2003, the European Parliament endorsed the creation of an Africa-based clinical trials program to test new medical products targeting AIDS, malaria and tuberculosis.
IAVI News
New Members for IAVI SAC, Board
Is Hormonal Contraceptive Use a Factor in HIV Vaccine Trials?
By Emily Bass
The choice to use—or not use—condoms impacts enormously on women’s risk of acquiring HIV.
Taking a Rights-Based Approach to AIDS Research
An Interview with David Patterson
Update on Merck's AIDS Vaccine Program
By Patricia Kahn
Since launching its first HIV vaccine clinical trials in 1999, Merck has emerged as a major player in the field, with over 600 people now enrolled in its preventive vaccine studies.
Vaccine Briefs
Global Fund Update: New Chair, New Call for Proposals
VaxGen Trial Yields Trove of Behavioral and Social Science Findings
By Emily Bass
When data from VaxGen’s completed AIDSVAX® trial were released in February, the media flurry focused on the efficacy results, which were disappointing.